This study shows that firms respond in strategic ways to institutional pressures that stem from social scandals. Through the formal analysis of the historical narrative of events, the authors studied how seven pharmaceutical companies reacted over the years to accusations of being socially irresponsible in dealing with the HIV virus in Africa. The analysis shows that institutional and task environmental factors interact to precipitate pharmaceutical companies' reactions. Although firms' behaviors were indeed affected by institutional pressures exerted by activist groups and the media, they did not passively adapt to these pressures. Instead, they decoupled their core technical activities from their policy announcements (by delaying the implementation of promised concessions) and used institutional pressure in the organizational field as a way of pursuing their own economic interests.
Act Up New York. (1999, June 18). Aids activists hit Al Gore three times in two days. Retrieved November 29, 2005, from http://www.globaltreatmentaccess.org/content/press_releases/99/061899_AU_PR_GORE.html
2.
Act Up New York. (2001, March 5). AIDS drugs for Africa march and rally. Retrieved November 29, 2005, from http://www.actupny.org/reports/march5.html
3.
Act Up Paris. (2002, May 15). Accelerating access serves pharmaceutical companies while corrupting health organizations. Retrieved November 29, 2005, from http://www.actupny.org/reports/Durban-accessPR.html
4.
Agence France-Press. (2000, December 1). Pfizer signs agreement to provide S. Africa with AIDS drug for free. Retrieved November 29, 2005, from http://www.aegis.com/news/afp/2000/AF001217.html
5.
Block, R. (2001, April 18). South Africa, drug firms near accord to settle court case over AIDS drugs. The Wall Street Journal, p. A3-A3.
6.
Cooper, H., Zimmerman, R., & McGinley, L. (2001, March 2). AIDS epidemic traps drug firms in a vise: Treatment vs. profits. The Wall Street Journal, p. A1-A1.
7.
Davis, I. (2005). What is the business of business?McKinsey Quarterly, 3, 104-113.
8.
Dawkins, C. E. (2005). First to market: Issue management pacesetters and the pharmaceutical industry response to AIDS in Africa. Business & Society, 44, 244-282.
9.
DiMaggio, P. J., & Powell, W. W. (1983). The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields. American Sociological Review, 48, 147-160.
10.
Elsbach, K. D. (1994). Managing organizational legitimacy in the California cattle industry: The construction and effectiveness of verbal accounts. Administrative Science Quarterly, 39, 57-88.
11.
Elsbach, K. D., & Sutton, R. I. (1992). Acquiring organizational legitimacy through illegitimate actions: A marriage of institutional and impression management theories. Academy of Management Journal, 35, 699-739.
12.
Freedman, A. M. (2001, April 6). Annan gains pledges from drug makers—Patent protection affirmed on AIDS medications for price cuts to poor. The Wall Street Journal, p. A2-A2.
13.
Frombrun, C., & Shanley, M. (1990). What's in a name: Reputation building and corporate strategy. Academy of Management Journal, 33, 233-259.
14.
Griffin, L. (1993). Narrative, event-structure analysis, and casual interpretation in historical sociology. American Journal of Sociology, 98, 1094-1133.
15.
Griffin, L., & Ragin, C. C. (1994). Some observations on formal methods of qualitative analysis. Sociological Methods and Research, 23, 4-21.
16.
Heise, D. R. (1989). Modeling event structures. Journal of Mathematical Sociology, 14, 139-169.
17.
Jones, P. M. (2000, December 24). Brazil's free AIDS-drug program slashes cases, earns global interest. Chicago Tribune, p. 5-5.
18.
Lawrence, P., & Lorsch, J. W. (1967). Differentiation and integration in complex organizations. Administrative Science Quarterly, 12, 1-47.
19.
Mahon, J. F., & Waddock, S. A. (1992). Strategic issues management: An integration of issue life cycle perspectives. Business & Society, 31, 19-32.
20.
Marcus, A. A., & Goodman, R. S. (1991). Victims and shareholders: The dilemmas of presenting corporate policy during a crisis. Academy of Management Journal, 34, 281-305.
21.
McNeil, D. G., Jr. (2000, July 9). Medicine merchants: Patents and patients. The New York Times, p. 8-8.
22.
Médecins Sans Frontières. (2001, February 23). Progress reported on implementation of offer for more affordable anti-AIDS drugs. Retrieved November 29, 2005, from http://www.accessmed-msf.org/prod/publications.asp?scntid=2182001442397&contenttype=PARA&
23.
Meyer, J., & Rowan, B. (1977). Institutionalized organizations: Formal structure as myth and ceremony. American Journal of Sociology, 83, 340-363.
24.
Milano, M., Berkman, A., & Hoos, D. (2000). Breaking the silence: Activists efforts to improve global access to AIDS medications. Retrieved November 30, 2005, from http://www.actupny.org/reports/milano.html
25.
Naik, G. (2001, February 22). GlaxoSmithKline profit jumps 13% as firm plans to boost AIDS efforts. The Wall Street Journal, p. A19-A19.
26.
Oliver, C. (1991). Strategic responses to institutional processes. Academy of Management Review, 16, 145-179.
27.
Oliver, C. (1997). The influence of institutional and task environment relationships on organizational performance. Journal of Management Studies, 34, 99-125.
28.
Oxfam. (2001a). Dare to lead: Public health and company wealth. Retrieved November 29, 2005, from http://www.oxfam.org.uk/what_we_do/issues/health/dare_to_lead.htm
29.
Oxfam. (2001b). Formula for fairness: Patient rights before patent rights. Retrieved November 29, 2005, from http://www.oxfam.org.uk/what_we_do/issues/health/cb_pfizer.htm
30.
Pfeffer, J., & Salancik, G. R. (1978). The external control of organizations: A resource dependence perspective. New York: Harper & Row.
31.
Poor markets, rich markets. (2004, October 2). The Economist, p. 65-65.
32.
Porter, M. E. (1979). How competitive forces shape strategy. Harvard Business Review, 57, 137-145.
33.
Profits and losses of AIDS. (1996, July 13). The Economist, p. 85-86.
34.
Ragin, C. C. (1987). The comparative method.Berkeley: University of California Press.
35.
Ross, J., & Staw, B. M. (1993). Organizational escalation and exit: Lessons from the Shoreham Nuclear Power Plant. Academy of Management Journal, 36, 701-733.
36.
Scott, W. R. (1998). Organizations: Rational, natural, and open systems (4th ed.). Upper Saddle River, NJ: Prentice Hall.
37.
Stevens, J. M., Steensma, H. K., Harrison, D. A., & Cochran, P. L. (2005). Symbolic or substantive document? The influence of ethics codes on financial executives' decisions. Strategic Management Journal, 26, 181-195.
38.
Stevenson, W. B., & Greenberg, D. (1998). The formal analysis of narratives of organizational change. Journal of Management, 24, 741-753.
39.
Stevenson, W. B., & Greenberg, D. (2000). Agency and social networks: Strategies of action in a social structure of position, opposition, and opportunity. Administrative Science Quarterly, 45, 651-678.
40.
Sutton, R. I., & Callahan, A. L. (1987). The stigma of bankruptcy: Spoiled organizational image and its managementAcademy of Management Journal, 30, 405-437.
41.
Symptomatic relief. (2003, September 6). The Economist, p. 13-13.
42.
Treatment Action Campaign. (2001, March 1). Put lives before profits! Retrieved November 29, 2005, from http://www.globaltreatmentaccess.org/content/press_releases/01/030101_TAC_COSATU_PA_SA.html
43.
United Nations. (2001, April 5). Secretary-General announces steps by leading drug companies to improve. Retrieved November 29, 2005, from http://www.unis.unvienna.org/unis/pressrels/2001/sgsm7764.html
44.
Waldholz, M. (1996, July 3). Precious pills: New AIDS treatment raises tough question of who will get it; For the poor, high costs, rigid regimens dim drug cocktails' promise a major issue for Medicaid. The Wall Street Journal, p. A1-A1.
45.
Waldholz, M. (1999, May 6). Foreign aid: Bristol-Myers heeds calls to bolster the war against HIV in Africa. The Wall Street Journal, p. A1-A1.
46.
Waldholz, M. (2000a, April 3). Pfizer plans to provide Diflucan drug at no cost to South Africans with AIDS. The Wall Street Journal, p. A3-A3.
47.
Waldholz, M. (2000b, July 7). Bristol best intentions: Bristol-Myers finds pledging AIDS aid is easier than giving it—In Botswana, many complain grants are misdirected, with too many strings—A request for “less fanfare.”The Wall Street Journal, p. A1-A1.
48.
Waldholz, M. (2000c, July 13). African nations discuss possibility of buying generic AIDS drugs. The Wall Street Journal, p. A3-A3.
49.
Waldholz, M. (2000d, March 24). Pfizer weighs requests to cut price of drug. The Wall Street Journal, p. B6-B6.
50.
Waldholz, M. (2000e, May 11). Makers of AIDS drugs agree to slash prices in Third World. The Wall Street Journal, p. A1-A1.
51.
Waldholz, M., & Harris, G. (2000, May 12). AIDS drug plan spurs call to cut prices elsewhere. The Wall Street Journal, p. B1-B1.
52.
Waldholz, M., & Zimmerman, R. (2001, March 15). Bristol-Myers offers to sell two AIDS drugs in Africa at below cost. The Wall Street Journal, p. B1-B1.
53.
Weaver, G. R., Treviño, L. K., & Cochran, P. L. (1999). Integrated and decoupled corporate social performance: Management commitments, external pressures, and corporate ethics practices. Academy of Management Journal, 5, 539-552.
54.
Westphal, J. D., & Zajac, E. J. (1994). Substance and symbolism in CEO's long term incentive plans. Administrative Science Quarterly, 39, 367-390.
55.
Westphal, J. D., & Zajac, E. J. (2001). Decoupling policy from practice: The case of stock repurchase programs. Administrative Science Quarterly, 46, 202-228.
56.
Williamson, O. E. (1981). The economics of organization: The transaction cost approach. American Journal of Sociology, 87, 548-577.
57.
Zimmerman, R. (2002, November 15). Roche is faulted for high cost of AIDS drug in poor countries. The Wall Street Journal, p. B2-B2.
58.
Zimmerman, R., Pesta, J., & Block, R. (2001, February 8). Cipla AIDS-drug offer changes outlook. The Wall Street Journal, p. B13-B13.
59.
Zimmerman, R., & Waldholz, M. (2001, March 27). Abbott to cut prices African AIDS drugs prices. The Wall Street Journal, p. A3-A3.
